首页 索伦托医疗(usSRNE)-基本信息

索伦托医疗(usSRNE)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:7.69

最高价:8.0

成交量:1.2272622E7

昨收价:7.74

最低价:7.48

最新价:7.51

行情图标
概要信息

中文名称:索伦托医疗


英文名称:Sorrento Therapeutics


简介:索伦托医疗公司是一家在开发阶段的生物制药公司,主要从事发现、开发、商业化新颖的候选治疗药物,用于治疗各种病况的病人,包括癌症、验证、代谢和感染疾病


电话:1-858-2034100


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

索伦托医疗公司正致力于使用自体T细胞开发基于嵌合抗原受体(CAR)的免疫疗法。Sorrento Therapeutics公司正在开发: CD38定向CAR-T,一种用于治疗多发性骨髓瘤,淀粉样变性和移植物抗宿主疾病的细胞疗法; CD123定向CAR-T用于治疗急性髓性白血病; 和人抗体,包括PD-1,PD-L1,CD38,CD123,CD47,c-MET,VEGFR2,CCR2,OX40,TIGIT和CD137; 索伦托医疗公司还在开发包含STAT3,突变KRAS,MYC,p53和TAU的细胞内靶向抗体,以调节癌症,炎症,自身免疫疾病,糖尿病,中枢神经系统疾病,心血管疾病和病毒感染的进化;和溶瘤病毒,感染和选择性繁殖和破坏肿瘤细胞而不损害健康组织; 此外,Sorrento Therapeutics还提供树脂毒素,一种非阿片类药物TRPV1激动剂神经毒素,用于治疗顽固性疼痛治疗; 和ZTlido,利多卡因递送系统,用于治疗带状疱疹后神经痛。索伦托医疗公司与Mabtech Limited签订了许可协议,以开发和商业化基于Erbitux,Remicade,Xolair和Simulect的多种预先指定的生物仿制药和生物抗体。

交易日期 交易人 职位 类型 交易份额 价格
2018-09-12 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 78677 4.92
2018-09-12 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 29137 5.01
2018-09-11 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 189754 5.06
2018-07-19 Ji (Henry H) Chief Executive Officer Buy 6000 1.75
2018-02-27 Ji (Henry H) Officer and Director Buy 124298 --
2018-02-27 Ji (Henry H) Officer and Director Buy 64600 9.95
2018-02-27 Ng (George K) Officer Buy 90000 9.95
2018-02-27 Ng (George K) Officer Buy 163469 --
2018-02-27 Ferrigno (Dean) Officer Buy 118 --
2018-02-06 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 150000 7.19
2018-02-05 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 512912 6.75
2018-02-04 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 37483 8.00
2018-02-04 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 16973 8.00
2018-02-04 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 16265 8.00
2018-01-29 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 53786 7.65
2018-01-29 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 57037 7.65
2018-01-29 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 124333 7.65
2018-01-28 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 39667 7.61
2018-01-28 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 17214 7.61
2018-01-28 ABG Management, Ltd. Beneficial Owner of More than 10% Class Sell 17963 7.61
2018-01-23 Asia Pacific MedTech (BVI), Ltd. Beneficial Owner of More than 10% Class Sell 577962 7.52
2018-01-22 Asia Pacific MedTech (BVI), Ltd. Beneficial Owner of More than 10% Class Sell 106326 7.82
2018-01-20 Ji (Henry H) Chief Executive Officer Buy 1801801 --
2017-09-10 Ji (Henry H) Chief Executive Officer Buy 67932 --
2017-09-10 Ng (George K) Officer Buy 89339 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Bank of Montreal 290761 0.24% 281884 3175.44% 2019-03-31
Invesco Capital Management LLC 1459737 1.19% -13474 -0.91% 2019-07-31
State Street Corporation 2117328 1.73% -3933470 -65.01% 2019-03-31
Northern Trust Investments Inc 2180653 1.78% 35019 1.63% 2019-07-31
Vanguard Investments Australia Ltd 2517935 2.05% -137 -0.01% 2019-07-31
BlackRock Fund Advisors 4024347 3.28% -243 -0.01% 2019-07-31
Vanguard Group Inc 4402843 3.59% 791161 21.91% 2019-03-31
China In Shine Investment Ltd. 4407713 3.59% 4407713 -- 2018-06-13
BlackRock Inc 7546509 6.15% -19729 -0.26% 2019-03-31
Northern Trust Investments N A 1333958 1.09% 73459 5.83% 2019-03-31
Parametric Portfolio Associates LLC 306798 0.25% 306798 -- 2019-03-31
BMO Asset Management Inc 290761 0.24% 283434 3868.35% 2019-03-31
AXA Equitable Funds Management Group, LLC 371867 0.30% -- -- 2019-07-31
Wildcat Capital Management, LLC 415765 0.34% -- -- 2019-03-31
BlackRock Institutional Trust Company NA 435715 0.36% -1181 -0.27% 2019-07-31
BlackRock 679814 0.55% 25616 3.92% 2019-07-31
State Street Global Advisors 1080134 0.88% -- -- 2019-07-31
Fidelity Management & Research Company 1321218 1.08% 170221 14.79% 2019-07-31
Geode Capital Management, LLC 1330747 1.09% -771013 -36.68% 2019-03-31
Northern Trust Corp 1333958 1.09% 73459 5.83% 2019-03-31
Deutsche Bank AG 947581 0.77% 546298 136.14% 2018-12-31
BlackRock Asset Management Canada Ltd 2507054 2.05% -1787 -0.07% 2019-05-31
Bank of New York Mellon Corp 422451 0.34% 25085 6.31% 2018-12-31
Morgan Stanley - Brokerage Accounts 2190901 1.79% 1894813 639.95% 2018-12-31
Ally Bridge Group Capital Partners II LP 7088903 5.78% -2449037 -25.68% 2018-02-06
D. E. Shaw & Co LP 894000 0.73% 7384 0.83% 2018-12-31
Citigroup Inc 880598 0.72% 554869 170.35% 2018-12-31
Renaissance Technologies Corp 806763 0.66% 710847 741.11% 2018-12-31
UBS Group AG 695226 0.57% 532674 327.69% 2018-12-31
SSGA Funds Management Inc 4352169 3.56% -25900 -0.59% 2019-02-28
Intellectus Partners, LLC 557026 0.46% -- -- 2018-09-30
Fidelity Management and Research Company 363300 0.30% 363300 -- 2018-09-30
FMR Inc 363300 0.30% 363300 -- 2018-09-30
Teachers Advisors LLC 401100 0.33% 234726 141.08% 2018-09-30
Amvescap Plc. 1368184 1.12% 1368184 -- 2018-09-30
Vanguard 439659 0.36% 23191 5.57% 2019-01-31
Fidelity SelectCo, LLC 399821 0.33% -- -- 2018-12-31
Rock Creek Group, LP 460000 0.38% -- -- 2018-06-30
Bank of America Corporation 442632 0.36% 279677 171.63% 2018-06-30
Man Group PLC 1342616 1.10% 1342616 -- 2018-03-31
Wells Fargo & Co 611968 0.51% 110768 22.10% 2018-06-30
Millennium Management LLC 264608 0.23% -1170062 -81.56% 2018-06-30
Columbia Management Company 298237 0.26% 153813 106.50% 2018-06-30
Candriam Luxembourg 310000 0.27% -- -- 2018-06-30
Invesco PowerShares Capital Mgmt LLC 1052470 0.78% -- -- 2018-09-13
Famous Sino Ltd. 4407713 3.82% 4407713 -- 2018-06-13
State Street Corp 7232063 6.22% 2073717 40.20% 2018-06-30
Asia Pacific MedTech (BVI) Ltd. 8617513 7.46% -684288 -7.36% 2018-06-13
Morgan Stanley & Co Inc 241550 0.21% 206922 597.56% 2018-06-30
BNY Mellon Investment Management 204936 0.18% 156273 321.13% 2018-06-30
UBS Securities LLC 442058 0.49% 418848 1804.60% 2018-03-31
Goldman, Sachs & Co. 472282 0.52% 439579 1344.15% 2018-03-31
Alambic Investment Management, L.P. 417034 0.46% 377182 946.46% 2018-03-31
Teachers Advisors Inc 357082 0.31% 357082 -- 2018-06-30
Vassalluzzo Scott J 266510 0.29% 266510 -- 2018-03-31
BlueCrest Capital Management Ltd. 282795 0.31% 282795 -- 2018-03-31
Oxford Asset Management, LLC 215601 0.26% 215601 -- 2017-12-31
Bogle Investment Management L P 155805 0.17% 155805 -- 2018-03-31
Susquehanna Financial Group, LLLP 168661 0.20% 168661 -- 2017-12-31
BlackRock Advisors (UK) Ltd 106655 0.13% 75955 247.41% 2017-12-31
Medical Strategy GmbH 80186 0.08% 40000 99.54% 2018-03-31
T. Rowe Price Associates, Inc. 77300 0.09% 77300 -- 2017-12-31
Apo Asset Management GmbH 65409 0.07% 30000 84.72% 2018-03-31
Matrix Asset Advisors Inc 72000 0.09% -- -- 2017-12-31
Infinity Q Capital Management, LLC 123597 0.16% -- -- 2017-11-30
Oppenheim Asset Mgmt Services S.¨¤ r.l. 181826 0.23% -- -- 2017-09-30
BlackRock Advisors LLC 95469 0.12% -3359 -3.40% 2018-02-28
J.P. Morgan Securities Inc 68179 0.08% -7990 -10.49% 2017-12-31
Wellington Management Company LLP 30662 0.04% -- -- 2018-01-31
Reichmuth & Co Privatbankiers 25928 0.03% -- -- 2018-01-31
Dimensional Fund Advisors, Inc. 36894 0.04% -- -- 2017-12-31
Crow Point Partners, LLC 44565 0.06% -52971 -54.31% 2017-09-30
Virtu Financial LLC 43348 0.06% 29258 207.65% 2017-09-30
KCG AMERICAS LLC 163931 0.21% 136506 497.74% 2017-06-30
Cormorant Asset Management, LLC 1690800 2.21% -- -- 2017-06-30
Element Capital Management LLC 219631 0.29% 219631 -- 2017-06-30
Sunrise Partners LLC 93900 0.12% 93900 -- 2017-06-30
FREJOY Investment Management Co Ltd 5306307 13.20% 5306307 -- 2016-06-07
ABG Management Ltd 4614067 11.47% 4614067 -- 2016-05-31
Henan Yulin Green Engineering Co Ltd 3613033 8.98% 3613033 -- 2016-06-07
venBio Select Advisor LLC 1531273 2.66% -124001 -7.49% 2016-09-30
Yuhan Corp 1801802 4.69% 1801802 -- 2016-04-29
Franklin Advisers Inc 339400 0.59% -- -- 2016-09-30
Putnam Investment Management,LLC 284536 0.49% 72675 34.30% 2016-09-30
Baird Robert W & Co, Inc. 162275 0.28% -48502 -23.01% 2016-09-30
TIAA-CREF Investment Management LLC 148406 0.26% -84351 -36.24% 2016-09-30
CommonWealth PPS 96154 0.17% -- -- 2016-09-30
Dr.Henry Ji 2343745 4.00% 28195252 0.10% 1999-11-30
Dr.Patrick Soon-Shiong 9632373 4.00% 115877447 0.30% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
TIAA-CREF Small-Cap Blend 172015 0.14% -- -- 2019-05-31
iShares Russell 2000 ETF 2569176 2.10% 5027 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 2494366 2.03% -- -- 2019-06-30
Vanguard Extended Market Index Fund 1321600 1.08% -4174 -0.31% 2019-06-30
iShares Russell 2000 Growth ETF 1060283 0.86% -- -- 2019-07-30
State Street Russell Small Cap 502636 0.41% -- -- 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 477642 0.39% -17678 -3.57% 2019-06-30
State Street Russell Small/Mid Cap 448868 0.37% -- -- 2019-06-30
NT R2000 Index Fund - NL 436034 0.36% 2055 0.47% 2019-06-30
NT R2000 Growth Index Fund - Lending 346397 0.28% 14983 4.52% 2019-06-30
Northern Trust Russell 2000 Index DC NL 331023 0.27% 434 0.13% 2019-06-30
iShares Russell 2000 Small-Cap Index Fd 174647 0.14% 14239 8.88% 2019-06-30
BlackRock Extended Equity Market 179009 0.15% 24040 15.51% 2019-06-30
The Vanguard - Russell 2000 Grwth Idx CF 219807 0.18% 16445 8.09% 2019-06-30
Russell 2000 Index Non-Lendable Fund E 235446 0.19% 6852 3.00% 2019-06-30
Schwab Small Cap Index Fund 243446 0.20% 9192 3.92% 2019-06-30
Vanguard Health Care Index Fund 256765 0.21% -2704 -1.04% 2019-06-30
Fidelity 465841 0.38% 75713 19.41% 2019-04-30
iShares Micro-Cap ETF 296160 0.24% -- -- 2019-07-30
Invesco DWA Healthcare Momentum ETF 1022216 0.83% -- -- 2018-09-30
Invesco DWA SmallCap Momentum ETF 335331 0.27% -- -- 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 2331985 1.90% -3915 -0.17% 2019-05-30
Vanguard Strategic Small Cap Equity Fund 622052 0.51% -190699 -23.46% 2018-12-31
Direxion Daily S&P Biotech Bull 3X Shrs 233269 0.19% 79468 51.67% 2019-02-28
AXA 2000 Managed Volatility Portfolio 161377 0.13% -- -- 2019-01-31
SPDR 4279436 3.50% -26148 -0.61% 2019-02-28
BlackRock Advantage Small Cap Growth Fd 114891 0.09% -- -- 2019-01-31
Vanguard Instl Total Stock Market Idx Fd 116393 0.10% -- -- 2019-01-31
Vanguard Russell 2000 Index Fund 129363 0.11% 271 0.21% 2019-01-31
Master Small Cap Index Series 133769 0.11% -- -- 2019-01-31
Vanguard Explorer Fund 258433 0.21% 29093 12.69% 2018-09-30
Virtus LifeSci Biotech Clinical Trls ETF 118437 0.10% -- -- 2019-01-30
AQR Small Cap Multi-Style Fund 171014 0.14% 84162 96.90% 2018-09-30
Fidelity Advisor 363300 0.30% -- -- 2018-11-30
Loncar Cancer Immunotherapy ETF 297964 0.24% -- -- 2018-11-30
Candriam Eqs L Biotechnology 310000 0.25% -- -- 2018-09-30
iShares Micro-Cap 233976 0.18% -- -- 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 214416 0.18% -168 -0.08% 2018-07-31
PowerShares DWA SmallCap Momentum ETF 276789 0.21% -- -- 2018-09-13
CREF Stock R1 257501 0.22% 125688 95.35% 2018-07-31
Vanguard Explorer Inv 229340 0.20% 229340 -- 2018-06-30
BlackRock Extended Equity Market K 153705 0.13% 4180 2.80% 2018-06-30
Fidelity Spartan 175528 0.15% 41193 30.66% 2018-07-31
Schwab Small Cap Index 162000 0.14% -- -- 2018-07-31
BlackRock Russell 2000 123029 0.11% 123029 -- 2018-06-30
The Vanguard Russell 2000 Growth Index 156720 0.13% 2868 1.86% 2018-07-31
BlackRock Russell 2500 120113 0.10% 120113 -- 2018-06-30
AXA 2000 Managed Volatility K 131775 0.11% -- -- 2018-07-31
PowerShares DWA Healthcare Momentum ETF 766663 0.57% -- -- 2018-09-13
iShares Russell 2000 Growth 842190 0.64% -812 -0.10% 2018-09-12
Vanguard Strategic Small-Cap Equity Inv 812751 0.70% 375288 85.79% 2018-06-30
Vanguard Extended Market Idx Inv 1216825 1.05% 240755 24.67% 2018-07-31
Vanguard Total Stock Mkt Idx 1708001 1.47% -- -- 2018-07-31
Vanguard Health Care ETF 151678 0.13% 1278 0.85% 2018-07-31
TIAA-CREF Small-Cap Blend Idx Inst 106071 0.09% 106071 -- 2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 108921 0.09% 23330 27.26% 2018-06-30
Vanguard Russell 2000 ETF 96698 0.08% 96698 -- 2018-06-30
AQR Small Cap Multi-Style N 86852 0.07% 86852 -- 2018-06-30
BioShares 108716 0.07% -- -- 2018-07-27
Vanguard Balanced Index Inv 42300 0.05% -- -- 2018-05-31
Vanguard Growth & Income Inv 70600 0.08% 64800 1117.24% 2018-03-31
Northern Small Cap Index 51085 0.04% 51085 -- 2018-06-30
iShares Core S&P Total US Stock Mkt 32890 0.03% -- -- 2018-06-29
T. Rowe Price Extended Equity Market Idx 44696 0.05% -32604 -42.18% 2018-03-31
BNY Mellon EB DL Mkt Completion 42306 0.05% -8044 -15.98% 2018-03-31
iShares Russell 3000 28730 0.02% -- -- 2018-06-28
BlackRock Disciplined Small Cp Cor Inv A 27710 0.03% -7071 -20.33% 2018-05-31
Bridgeway Ultra-Small Company 31500 0.03% -- -- 2018-03-31
BlackRock Small Cap Growth Eq Instl 24250 0.03% -- -- 2018-05-31
Cornerstone Advisors Glbl Public Eq Inst 26900 0.03% 7000 35.18% 2018-03-31
Bogle Small Cap Growth Instl 53105 0.06% 53105 -- 2018-03-31
Cornerstone Advisors Public Alts Instl 20700 0.02% 20700 -- 2018-03-31
AXA/Lord Abbett Micro Cap K 13293 0.02% -- -- 2018-02-28
BlackRock Master Small Cap Growth Port 15323 0.02% -- -- 2018-02-28
The Vanguard Total Stock Market Index 18036 0.02% 3067 20.49% 2018-03-31
DFA US Micro Cap I 13797 0.02% -- -- 2018-02-28
Infinity Q Diversified Alpha Instl 123597 0.16% -- -- 2017-11-30
EAS Crow Point Alternatives A 44565 0.06% -- -- 2017-09-30
BNY Mellon Market Completion Fund UC1 24967 0.03% 23865 2165.61% 2017-09-30
USAA Extended Market Index 6112 0.01% -- -- 2017-09-30
Master Extended Market Index Series 6112 0.01% -- -- 2017-11-30
Northern Small Cap Core 19852 0.03% -1000 -4.80% 2017-09-30
Vantagepoint Mid/Small Company Index I 4542 0.01% -- -- 2016-09-30
Christian Bros CUIT Small Cap Eqty Idx B 7600 0.01% -- -- 2016-09-30
Mutual of America Small Cap Growth 137696 0.24% -- -- 2016-09-30
Franklin Biotechnology Discovery A 132951 0.23% -- -- 2016-12-31
Vanguard VIF Small Co Gr 30555 0.05% -- -- 2016-09-30
Putnam Global Health Care A 42883 0.07% -146417 -77.35% 2016-12-31
Franklin Biotechnology Discovery 206449 0.60% -- -- 2015-07-31
FCP OP MEDICAL BioHealthTrends 192538 0.50% 40000 26.20% 2015-09-30
Putnam Global Health Care Fund 189300 0.50% 189300 -- 2015-09-30
Carnegie Global Healthcare 182301 0.50% -- -- 2015-10-31
iShares Russell 2000 (AU) 453364 1.10% -570 -0.10% 2015-11-19
CREF Stock Account 152105 0.40% -- -- 2015-09-30
Mutual of America Small Cap Growth Fund 119674 0.30% -- -- 2015-06-30
Highland Long/Short Healthcare Fund 111780 0.30% 111780 -- 2015-06-30
APO Medical Opportunities 107460 0.30% 34000 46.30% 2015-10-31
Fidelity Spartan® Extended Mkt Indx Fd 103269 0.30% -- -- 2015-09-30
Franklin Biotechnology Discovery Fund 132951 0.40% -- -- 2015-09-30

Kim D. Janda Kim D. Janda is on the board of Sorrento Therapeutics, Inc. and Worm Institute For Research & Medicine and Professor at The Scripps Research Institute. Dr. Janda received an undergraduate degree from the University of South Florida and a doctorate from the University of Arizona.
David Lemus David Lemus holds the position of Chief Operating & Financial Officer for Proteros biostructures GmbH and Treasurer & Director at Biohealth Innovation, Inc. Mr. Lemus is also on the board of Silence Therapeutics Plc, Pharmaceutical Manufacturers Association of America, Sorrento Therapeutics, Inc. and Mit Club of Washington Dc. In the past David Lemus occupied the position of Chief Operating & Financial Officer of MediGene AG and Chief Executive & Financial Officer of MediGene, Inc. (a subsidiary of MediGene AG), Chief Financial Officer & Executive Vice President at MorphoSys AG, Treasury Consultant at Electrolux AB, Treasurer of Chocoladefabriken Lindt & Spr�0�1�0�4ngli AG, Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. and Operations Manager & Project Manager-Global IT at Hoffman-La Roche, Inc. Mr. Lemus received a graduate degree from Massachusetts Institute of Technology and an undergraduate degree from the University of Maryland.
Jaisim Shah Jaisim Shah is Chief Executive Officer & Director at Semnur Pharmaceuticals, Inc. He is also on the board of SCILEX Pharmaceuticals, Inc., Sorrento Therapeutics, Inc. and Celularity, Inc. In the past Mr. Shah was President at Azelon Pharmaceuticals, Inc., Chief Business Officer & Senior Vice President at PDL BioPharma, Inc. and Senior VP-Marketing & Medical Affairs at Protein Design Labs, Inc. (a subsidiary of PDL BioPharma, Inc.), Chief Business Officer & SVP-Business Development at CytRx Corp., Vice President-Global Marketing at Bristol-Myers Squibb Co., Chief Business Officer & Senior Vice President at Elevation Pharmaceuticals, Inc., Chief Business Officer at Pulmatrix Operating Co., Inc. and Chief Business Officer & Senior Vice President at Abbott Biotherapeutics Corp. Jaisim Shah received a graduate degree from the University of Akron and an MBA from the University of Oklahoma.
Jaisim Shah Jaisim Shah is Chief Executive Officer & Director at Semnur Pharmaceuticals, Inc. He is also on the board of SCILEX Pharmaceuticals, Inc., Sorrento Therapeutics, Inc. and Celularity, Inc. In the past Mr. Shah was President at Azelon Pharmaceuticals, Inc., Chief Business Officer & Senior Vice President at PDL BioPharma, Inc. and Senior VP-Marketing & Medical Affairs at Protein Design Labs, Inc. (a subsidiary of PDL BioPharma, Inc.), Chief Business Officer & SVP-Business Development at CytRx Corp., Vice President-Global Marketing at Bristol-Myers Squibb Co., Chief Business Officer & Senior Vice President at Elevation Pharmaceuticals, Inc., Chief Business Officer at Pulmatrix Operating Co., Inc. and Chief Business Officer & Senior Vice President at Abbott Biotherapeutics Corp. Jaisim Shah received a graduate degree from the University of Akron and an MBA from the University of Oklahoma.
Jaisim Shah Jaisim Shah is Chief Executive Officer & Director at Semnur Pharmaceuticals, Inc. He is also on the board of SCILEX Pharmaceuticals, Inc., Sorrento Therapeutics, Inc. and Celularity, Inc. In the past Mr. Shah was President at Azelon Pharmaceuticals, Inc., Chief Business Officer & Senior Vice President at PDL BioPharma, Inc. and Senior VP-Marketing & Medical Affairs at Protein Design Labs, Inc. (a subsidiary of PDL BioPharma, Inc.), Chief Business Officer & SVP-Business Development at CytRx Corp., Vice President-Global Marketing at Bristol-Myers Squibb Co., Chief Business Officer & Senior Vice President at Elevation Pharmaceuticals, Inc., Chief Business Officer at Pulmatrix Operating Co., Inc. and Chief Business Officer & Senior Vice President at Abbott Biotherapeutics Corp. Jaisim Shah received a graduate degree from the University of Akron and an MBA from the University of Oklahoma.
Jiong Shao Jiong Shao holds the position of Chief Financial Officer & Executive Vice President at Sorrento Therapeutics, Inc. He previously was Managing Director & Head-US Office at CEC Capital Corp., MD & Head-China TMT Investment Banking at Deutsche Bank AG (Hong Kong), Managing Director at Macquarie Capital Ltd., Executive Director at Nomura International (Hong Kong) Ltd., Research Analyst at Lehman Brothers Asia Ltd. (Hong Kong) and Vice President of Lehman Brothers, Inc. Jiong Shao received an MBA from The Fuqua School of Business and an undergraduate degree from Shanghai Jiao Tong University.
Yue Wu Founder of Crown Bioscience International, Unimicro Technologies, Inc. and Crown Bioscience, Inc., Yue Wu is an entrepreneur is on the board of CASI Pharmaceuticals, Inc., SCILEX Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. He previously occupied the position of Chief Operating Officer for Unimicro Technologies, Inc., Chief Business Officer for Starvax, Inc., Head-Asian Operations at Burrill & Co. LLC, Chief Business Officer of Starvax International, Inc. (China), President, CEO & Chief Scientific Officer at Crown Bioscience, Inc., President, Chief Executive & Scientific Officer at Crown Bioscience International and Manager-Business Development & Strategic Planning at F. Hoffmann-La Roche Ltd. He received an undergraduate degree from Fudan University, a doctorate and an MBA from the University of California, Berkeley and a graduate degree from the University of Illinois.
Jerome B. Zeldis Jerome B. Zeldis founded Trek Therapeutics. Dr. Zeldis occupies the position of Chairman at MetaStat, Inc., Chairman for Trek Therapeutics and Chief Medical Officer & President-Regulatory at Sorrento Therapeutics, Inc. Dr. Zeldis is also on the board of 10 other companies. In the past he held the position of Chief Executive Officer at Celgene Global Health, Chief Medical Officer of Celgene Corp., Chief Medical Officer for Celularity, Inc., Chairman at Alliqua BioMedical, Inc., Associate Director at Sandoz Research Institute, Professor-Clinical Medicine at Robert Wood Johnson Medical School, Associate Professor-Medicine at the University of California, Associate Professor at the University of California, Davis, Assistant Professor at Harvard Medical School and Clinical Associate Professor at Weill Cornell Medical College. Jerome B. Zeldis received a graduate degree and an undergraduate degree from Brown University and a graduate degree and a doctorate from Yale University.
Mark Brunswick Mark Brunswick occupies the position of Vice President-Regulatory Affairs & Quality at Sorrento Therapeutics, Inc. In the past Dr. Brunswick held the position of Head-Regulatory Affairs & Quality at Sophiris Bio, Inc., Head-Regulatory Affairs at Arena Pharmaceuticals, Inc. and Director-Regulatory Affairs at Elan Biopharmaceuticals, Inc. Dr. Brunswick received a doctorate from University College London.
Jerome B. Zeldis Jerome B. Zeldis founded Trek Therapeutics. Dr. Zeldis is Chairman of MetaStat, Inc., Chairman at Trek Therapeutics, Chief Medical Officer for Celularity, Inc. and Chief Medical Officer & President-Regulatory at Sorrento Therapeutics, Inc. He is also Associate Professor at the University of California and on the board of 9 other companies. In the past Jerome B. Zeldis occupied the position of Chairman of Alliqua BioMedical, Inc., Chief Executive Officer of Celgene Global Health, Chief Medical Officer & CEO-Global Health at Celgene Corp., Associate Director at Sandoz Research Institute, Associate Professor at Weill Cornell Medical College, Assistant Professor at Harvard Medical School, Professor at Robert Wood Johnson Medical School and Associate Professor at the University of California, Davis. Dr. Zeldis received a graduate degree and an undergraduate degree from Brown University and a doctorate and a graduate degree from Yale University.
Henry H. Ji Henry H. Ji is an entrepreneur and businessperson who founded Sorrento Therapeutics, Inc., Sorrento Therapeutics, Inc., BioVintage, Inc. and Stratagene Genomics, Inc. and who has been at the head of 5 different companies. He occupies the position of Chairman, President & Chief Executive Officer for Sorrento Therapeutics, Inc., President & Chief Executive Officer of Scintilla Pharmaceuticals, Inc. and Chief Executive Officer & Director at SCILEX Pharmaceuticals, Inc. (both are subsidiaries of Sorrento Therapeutics, Inc.) and President of BioVintage, Inc. Dr. Ji is also on the board of Celularity, Inc. In the past Henry H. Ji occupied the position of Managing Director at Hongye SD Group LLC, President & Chief Executive Officer at Stratagene Genomics, Inc., Director & Chief Scientific Officer at Sorrento Therapeutics, Inc., Chief Scientific Officer & Secretary at Quikbyte Software, Inc., Vice President of Stratagene Corp. and Vice President-Sales & Business Development at CombiMatrix Corp. Henry H. Ji received a doctorate from the University of Minnesota and an undergraduate degree from Fudan University.
Dorman Followwill Dorman Followwill is on the board of Sorrento Therapeutics, Inc. and Senior Partner-Transformational Health at Frost & Sullivan, Inc. He received an undergraduate degree from Stanford University.
David Lemus David Lemus holds the position of Chief Operating & Financial Officer for Proteros biostructures GmbH and Treasurer & Director at Biohealth Innovation, Inc. Mr. Lemus is also on the board of Silence Therapeutics Plc, Pharmaceutical Manufacturers Association of America, Sorrento Therapeutics, Inc. and Mit Club of Washington Dc. In the past David Lemus occupied the position of Chief Operating & Financial Officer of MediGene AG and Chief Executive & Financial Officer of MediGene, Inc. (a subsidiary of MediGene AG), Chief Financial Officer & Executive Vice President at MorphoSys AG, Treasury Consultant at Electrolux AB, Treasurer of Chocoladefabriken Lindt & Spr�0�1�0�4ngli AG, Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. and Operations Manager & Project Manager-Global IT at Hoffman-La Roche, Inc. Mr. Lemus received a graduate degree from Massachusetts Institute of Technology and an undergraduate degree from the University of Maryland.
Jaisim Shah Jaisim Shah is Chief Executive Officer & Director at Semnur Pharmaceuticals, Inc. He is also on the board of SCILEX Pharmaceuticals, Inc., Sorrento Therapeutics, Inc. and Celularity, Inc. In the past Mr. Shah was President at Azelon Pharmaceuticals, Inc., Chief Business Officer & Senior Vice President at PDL BioPharma, Inc. and Senior VP-Marketing & Medical Affairs at Protein Design Labs, Inc. (a subsidiary of PDL BioPharma, Inc.), Chief Business Officer & SVP-Business Development at CytRx Corp., Vice President-Global Marketing at Bristol-Myers Squibb Co., Chief Business Officer & Senior Vice President at Elevation Pharmaceuticals, Inc., Chief Business Officer at Pulmatrix Operating Co., Inc. and Chief Business Officer & Senior Vice President at Abbott Biotherapeutics Corp. Jaisim Shah received a graduate degree from the University of Akron and an MBA from the University of Oklahoma.
Jiong Shao Jiong Shao holds the position of Chief Financial Officer & Executive Vice President for Sorrento Therapeutics, Inc. He is also on the board of CM Seven Star Acquisition Corp. In his past career he was Managing Director at CEC Capital Corp., Managing Director at Deutsche Bank AG (Hong Kong), Strategist & Research Analyst at Macquarie Capital Ltd., Research Analyst at Nomura International (Hong Kong) Ltd., Research Analyst at Lehman Brothers Asia Ltd. (Hong Kong) and Vice President for Lehman Brothers, Inc. He received an MBA from The Fuqua School of Business and an undergraduate degree from Shanghai Jiao Tong University.
Deborah H. Telman Deborah H. Telman occupies the position of Senior Vice President & General Counsel at Sorrento Therapeutics, Inc. In the past Ms. Telman occupied the position of Chief-Counsel Mergers & Acquisitions at The Boeing Co., Partner at Winston & Strawn LLP and Divisional VP & Associate General Counsel at Abbott Laboratories. Ms. Telman received a graduate degree from Boston University School of Law and an undergraduate degree from the University of Pennsylvania.
Bill Farley Currently, Bill Farley is Vice President-Sales & Business Development at Sorrento Therapeutics, Inc. In his past career Mr. Farley occupied the position of Vice President-Business Development at ChemDiv, Inc. and Vice President-Key Accounts at Wuxi Apptec, Inc. He received an undergraduate degree from The State University of New York.
Hui Li Hui Li is VP-Business Development & GM-China Operations at Sorrento Therapeutics, Inc. In the past Dr. Li occupied the position of Head--Business Development at BioDuro LLC, Executive Director-Business Development at Pharmaceutical Product Development LLC and Chief Executive Officer of Levena Biopharma US, Inc. Hui Li received an undergraduate degree from Peking University and a doctorate from the University of California San Diego.
Robert Knight Robert Knight occupies the position of Vice President-Clinical Research at Sorrento Therapeutics, Inc. In the past Dr. Knight held the position of Corporate Vice President at Celgene Corp. Dr. Knight received a doctorate from The State University of New York.
Stephen L Klincewicz Stephen L Klincewicz occupies the position of VP-Pharmacovigilance & Clinical Operations at Sorrento Therapeutics, Inc. Mr. Klincewicz received an undergraduate degree from McGill University, a doctorate from Des Moines University, a graduate degree from The Medical College of Wisconsin, Inc. and a graduate degree from Widener University.

量化对比

全部评论 2

  • 市场消息:Sorrento Therapeutics(SRNE.O)公司将以1亿美元总价收购药物发现和开发公司Antisense Therapeutics Limited(ANP)。

  • 【浙产未上市药获准在美国用于中重度新冠肺炎Ⅱ期临床研究】一款在浙江衢州市生产的第三代抗肺癌口服靶向药,将在美国开展针对中重度新冠肺炎患者的Ⅱ期临床研究。这款名叫“艾维替尼”的原研药在中国尚未获批上市,仍在国家药品监督管理局“优先审评”中。这项临床研究将由美国纳斯达克上市企业索伦托医疗公司开展。(澎湃)

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐